Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia

Abstract

The purpose of our investigation was to analyze the relationship between the serum levels of fatty acids and their metabolites and the levels of the selected metabolic and hormonal parameters in patients with benign prostatic hyperplasia (BPH) with regard to concomitant metabolic syndrome (MetS). We determined serum concentrations of total (TT) and free testosterone (FT), insulin (I), dehydroepiandrosterone sulphate (DHEAS), luteinizing hormone and insulin-like growth factor 1 (IGF-1) and sex hormone-binding globulin (SHBG). Gas chromatography was performed. The patients differed in terms of hormone levels, but only the differences in SHBG and IGF-1 levels were statistically significant. Analysis of the levels of polysaturated fatty acids in BPH patients showed that MetS contributed to changes in the levels of these acids. We also analyzed the relationship between the levels of fatty acids and diagnostic parameters for MetS. Particular abnormalities were associated with single changes in the levels of fatty acids. In the diabetic patients, changes in the levels of pentadecanoic acid, heptadecanoic acid and cis-11-eicosenoic acid were demonstrated. Our findings indicate the necessity for further investigation concerning the levels of fatty acids and their impact on the development of MetS, as well as the course and clinical picture of BPH.

Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

“…Low testosterone levels in ageing men and the subsequent hypogonadism are associated with different complications such as MetS and the risk of CVD [3,4,[42][43][44]. Additionally, liver steatosis is known to be symptomatic of metabolic dysfunction and could be considered as a hepatic indicator of MetS.…”

“…NAFLD is a liver inflammation that can lead to cirrhosis, liver failure, and often hepatocarcinoma [2]. Hepatic steatosis is also associated with an increase incidence of metabolic syndrome (MetS), T2DM, and obesity, where the key components of these diseases include hyperinsulinaemia, dyslipidaemia, and insulin resistance [3,4]. The prevalence of NAFLD ranges from 50% to 75% in patients with T2DM and in obese patients from 80% to 90% [5][6][7][8][9][10][11].…”

Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia

“…For example, SNPs in CYP17, CYP19, VDR, and SRD5A2 [ 34 ] and in chemokine genes CCR2 (rs1799864) and CCL5 (rs2107538) [ 45 ] genes have been reported in BPH. Individuals with metabolic syndrome (MetS) or its individual components—including central obesity, hyperinsulinemia, insulin resistance, and dyslipidemia, are more prone to develop BPH and LUTS [ 46 – 48 ]. However, the molecular and stromal mechanisms involved in the pathogenesis of BPH have not yet been fully elucidated.…”